PROSCA/BLADDR 2023 | Challenges in staging urinary tract tumors

Eva Compérat, MD, PhD, Medical University of Vienna in Austria, discusses challenges in accurately staging urinary tract tumors and how these impact treatment decisions. Material dependency poses a problem, and while cytology is helpful, it doesn’t resolve all issues. Pathologists face challenges in bladder wall assessment, as variations in appearance can lead to interpretation difficulties. Staging bladder tumors involves careful reporting due to variations in bladder wall structure. Sub-staging T1 tumors is debated, and despite recommendations since 2016, standardization is lacking. Interobserver variability exists, impacting T3 tumor assessment and prognostic implications. Prof. Compérat emphasizes the importance of meticulous evaluation, highlighting the potential benefits of using block resections for clearer views and reduced artifacts in pathology. This interview took place at the Global Congress on Prostate and Bladder Cancer (PROSCA/BLADDR) 2023 in Malaga, Spain.

These works are owned by Magdalen Medical Publishing (MMP), protected by copyright laws and treaties globally, with all rights reserved.